Treace Medical Concepts (TMCI)
(Delayed Data from NSDQ)
$6.65 USD
+0.01 (0.15%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $6.66 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TMCI 6.65 +0.01(0.15%)
Will TMCI be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TMCI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMCI
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
TMCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates
Other News for TMCI
Treace Medical Concepts: Facing Increasing Competitive Pressure
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
Treace Medical director buys $253.5K in common stock
Fly Intel: After-Hours Movers
Treace to Present at Truist Securities MedTech Conference